Boston Ventures

Boston Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing a diverse portfolio of high-potential therapies across multiple therapeutic areas, including liver disease, oncology, and immunology. The company operates with a unique business model, acquiring or licensing promising drug candidates from other pharmaceutical and biotech firms to accelerate their clinical development. Its lead program, BOS-580, is a long-acting FGF21 analog currently being evaluated in Phase 2 trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). By leveraging a lean, expert-led team and a robust capital structure, Boston Pharmaceuticals aims to efficiently bridge the gap between early-stage discovery and late-stage commercialization.